Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.19)
# 423
Out of 4,884 analysts
63
Total ratings
53.49%
Success rate
15.67%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $13.01 | -30.82% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $37.68 | -12.42% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $126.96 | +49.65% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $100.90 | -0.89% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.17 | -5.80% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $351.92 | +10.82% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $59.18 | -7.06% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $50.18 | +9.61% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $120.66 | +32.60% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $427.76 | +56.63% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $74.48 | +7.41% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.64 | +254.92% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,205.65 | +16.12% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $11.48 | -47.74% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $42.47 | +111.94% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $202.50 | +33.33% | 4 | Dec 20, 2023 |
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $13.01
Upside: -30.82%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $37.68
Upside: -12.42%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $126.96
Upside: +49.65%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $100.90
Upside: -0.89%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.17
Upside: -5.80%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $351.92
Upside: +10.82%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $59.18
Upside: -7.06%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $50.18
Upside: +9.61%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $120.66
Upside: +32.60%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $427.76
Upside: +56.63%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $74.48
Upside: +7.41%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.64
Upside: +254.92%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,205.65
Upside: +16.12%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $11.48
Upside: -47.74%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $42.47
Upside: +111.94%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $202.50
Upside: +33.33%